A recent study has found microscopic irregularities in the blood of individuals suffering from long COVID, which might help elucidate the enduring symptoms associated with the condition. These unusual structures, detected via advanced imaging methods, indicate a notable deviation from normal blood composition. If these findings are validated, they could significantly alter our understanding and diagnosis of long COVID, perhaps even providing a concrete target for future treatments.
Microclots and Immune Structures: Hidden Factors Behind Ongoing Illness
As researchers continue to unravel the causes of long COVID—an enigma that remains after years of the pandemic—a collaborative team of scientists has focused on blood analysis. Their research, published in the Journal of Medical Virology, indicates that those with long COVID have consistently elevated levels of two lesser-known but potentially dangerous factors: microclots and neutrophil extracellular traps, or NETs. Although these substances are naturally occurring, they seem to turn harmful when they unnecessarily accumulate and interact in abnormal ways.
“These aren’t the types of clots one would encounter during a stroke or pulmonary embolism,” says Dr. Alain Thierry, the lead researcher and a geneticist at Montpellier University in France. Instead, they are remarkably small—microscopic in size—but capable of disrupting blood flow in tiny vessels, particularly in vital areas such as the brain, muscles, and lungs.
The research team employed imaging flow cytometry and fluorescence microscopy on blood samples from 50 long COVID patients and 38 healthy controls. They discovered that microclots were nearly 20 times more prevalent in those with long COVID. Surprisingly, they also noted that NETs were not merely floating; they were integrated into the microclots themselves.
“This study establishes a strong link between biomarkers indicative of thromboinflammatory activity and long COVID,” the team noted.
The researchers suggest that these intertwined NETs and clots may form structures resistant to the body’s normal processes for clearing blood, which could directly account for symptoms like brain fog, fatigue, and chronic pain.
When Immune Defense Turns Inward: Self-Sabotage of the Body’s Defenses
NETs typically serve as a crucial part of the immune system’s defense. These sticky webs of DNA and enzymes, produced by white blood cells, ensnare invading pathogens before they can spread. Normally, NETs are quickly dismantled after fulfilling their role. However, the study found that in long COVID patients, NETs tend to persist in large amounts, becoming intertwined with microclots and potentially exacerbating the damage.
“The identification of these biomarker connections not only suggests a possible new diagnostic approach,” the authors argue, “but also introduces novel therapeutic targets, paving the way for significantly improved clinical management.”
While previous studies have noted microclots and NETs separately in other conditions, their combined presence and interaction in long COVID is a striking new revelation. This link might help explain why some individuals continue to experience symptoms long after the initial infection has resolved.
“This finding indicates that there are physiological interactions between microclots and NETs that, when dysregulated, may become pathogenic,” Thierry remarked.
In essence, the body’s immune response may be inadvertently forming self-sustaining, harmful blood structures that prolong the illness. This could also shed light on why typical diagnostic tests often miss long COVID; these interactions transpire at a microscopic level and may not be detected with conventional methods.
Towards a Blood Test? AI Uncovers the Undetectable
One of the remarkable components of the study was the use of artificial intelligence to analyze anonymized blood samples. The AI achieved a 91% accuracy rate in identifying long COVID patients based solely on the presence and patterns of microclots and NETs. This opens the door for a potentially reliable diagnostic blood test for a condition that has primarily relied on self-reported symptoms until now.
If realized, this could change how doctors approach screening and managing long COVID and might even facilitate personalized treatme
nts aimed at dissolving these stubborn blood structures. While clinical applications are still quite distant, the findings provide a promising direction. The authors caution, however, that more investigation is required to establish causation rather than just correlation. Still, the patterns they’ve identified represent a significant advancement. If later research confirms them, the blood of long COVID patients might not only aid in diagnosis but also in devising treatment strategies that could finally offer relief to many.
